Deals this week: Innopharmax, Aurinia Pharmaceuticals, Hainan Poly Pharm


Taiwanese pharmaceutical company Innopharmax intends to issue five million shares of its common stock in order to raise funds for meeting its research and development expenses and working capital.

The issue will be priced between NT$23 ($0.72) and NT$32 ($1.03) a share, with 85% of the shares issued to existing shareholders and 15% to the company’s employees.

Aurinia Pharmaceuticals has announced the pricing for its proposed underwritten public offering of shares to raise funds for research and development, and working capital.

The offering includes 22.3 million shares of its common stock priced at $6.75 a share to raise $150.5m in gross proceeds.

Underwriters have a 30-day option to purchase up to an additional 3.3 million shares.

"Aurinia Pharmaceuticals has announced the pricing for its proposed underwritten public offering of shares to raise funds for research and development, and working capital."

Aurinia Pharmaceuticals is a Canadian-based biopharmaceutical company focused on immunology.

Chinese pharmaceutical company Hainan Poly Pharm plans to raise ¥350.45m ($50.75m) in gross proceeds through an initial public offering (IPO) of its shares.

The IPO will include 30.5 million shares priced at ¥11.49 ($1.66) a share.

OncBioMune Pharmaceuticals has signed a non-binding agreement with Eddingpharm (Taizhou)’s subsidiary EOC Pharma for the development and commercialisation of the latter’s products in 34 countries across Mexico, Central and Latin America.

Based in the US, OncBioMune Pharmaceuticals is a biopharmaceutical company that develops novel cancer products and vaccine technology.